Hybio Pharmaceutical
Overview
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides,
Employees1226
Market Cap$20.2B
Revenue$955.5M
Listed OnShenzhen Stock Exchange
Ticker300199
CEOMr. Shaogui Zeng
HeadquartersWuhan